About the Study
The research study will compare two different strengths of doxorubicin microneedle array (D-MNA) with placebo (no active ingredient) on nodular basal cell carrcinoma (nBCC).
D-MNA is investigational. It is a small patch with very small dissolvable (melts by itself) needles, containing a cancer drug called doxorubicin at the needle tips.
This study will look at how safe they are and how both strengths of the D-MNA and placebo will work on nBCC.
The study will last up to 12 weeks, with one weekly treatment for three weeks and two follow-up visits.
Therapeutics, Inc. is conducting a clinical trial for males and females ages 18 and older to participate in a skin cancer clinical research study.
We are looking for volunteers with confirmed nBCC skin lesions to participate in this study. Qualified participants will receive compensation for their time and travel.